What is Atossa Therapeutics Inc's earnings per share (EPS)?

Atossa Therapeutics Inc (ATOS) reported diluted earnings per share of -$4.04 for fiscal year 2025. This represents a -32.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atossa Therapeutics Inc Financials

ATOS

FY2025 annual

Revenue Not reported for FY2025

Net Income -$34.8M -36.3% YoY

EPS (Diluted) -$4.04 -32.9% YoY

Free Cash Flow -$29.8M -41.5% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

This page shows Atossa Therapeutics Inc (ATOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATOS FY2025 2026-05-08

Atossa’s economics are those of a cash-funded development program, where research spending rather than debt or fixed assets drives results.

Over the last three fiscal years, cash nearly halved from $88.5M to $41.3M. Operating cash burn moved from -$20.9M to -$29.8M, and with capex trivial, that drain reflects the cost of sustaining a larger development effort rather than building long-lived operating assets.

The close match between net loss at -$34.8M and operating cash flow at -$29.8M means reported losses are not being masked by large noncash adjustments. With annual capex of only $23K, this is an asset-light burn model, so the income statement is a fairly direct guide to yearly cash needs and operating scale.

The balance sheet remains debt-light, with liabilities of $8.3M against cash of $41.3M, so the immediate pressure comes from spending pace rather than lenders. Because no financing cash came in during FY2025 while R&D spending increased and administrative costs stayed elevated, the company funded a bigger research push from a smaller cash base.

Financial Health Signals

Financial health score not available

Atossa Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Atossa Therapeutics Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Atossa Therapeutics Inc reported a net loss of $34.8M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$37.1M

YoY-34.5%

Atossa Therapeutics Inc's EBITDA was -$37.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 34.5% from the prior year.

Net Income

-$34.8M

YoY-36.3%

Atossa Therapeutics Inc reported -$34.8M in net income in fiscal year 2025. This represents a decrease of 36.3% from the prior year.

EPS (Diluted)

-$4.04

YoY-32.9%

Atossa Therapeutics Inc earned -$4.04 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 32.9% from the prior year.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$29.8M

YoY-41.5%

Atossa Therapeutics Inc recorded an outflow of $29.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 41.5% from the prior year.

Cash & Debt

$41.3M

YoY-41.9%

5Y CAGR+0.9%

10Y CAGR+27.2%

Atossa Therapeutics Inc held $41.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

YoY0.0%

Atossa Therapeutics Inc had 9M shares outstanding in fiscal year 2025. That is unchanged from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-88.3%

YoY-52.7pp

5Y CAGR-22.7pp

10Y CAGR+332.9pp

Atossa Therapeutics Inc's ROE was -88.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 52.7 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$21.2M

YoY+50.1%

5Y CAGR+26.2%

10Y CAGR+24.5%

Atossa Therapeutics Inc invested $21.2M in research and development in fiscal year 2025. This represents an increase of 50.1% from the prior year.

Capital Expenditures

$23K

YoY+21.1%

5Y CAGR+20.6%

Atossa Therapeutics Inc invested $23K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 21.1% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

ATOS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATOS annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K-95.6%	$40K-93.7%	$633K+31.3%	$482K+32022.8%	$2K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$132K	$0-100.0%	$346K+866.6%	$36K+592.2%	$5K
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$131K-425.5%	$40K-70.7%	$137K-67.1%	$416K+535.0%	-$96K
R&D Expenses	N/A	$21.2M+50.1%	$14.1M-18.6%	$17.3M+14.9%	$15.1M+63.8%	$9.2M+39.4%	$6.6M-0.6%	$6.6M+57.8%	$4.2M+80.8%	$2.3M+202.2%	$770K-67.3%	$2.4M+112.5%	$1.1M+0.5%	$1.1M-44.0%	$2.0M	N/A
SG&A Expenses	N/A	$16.0M+18.2%	$13.5M-3.8%	$14.0M+11.4%	$12.6M+11.5%	$11.3M+41.4%	$8.0M-24.7%	$10.6M+47.0%	$7.2M+48.7%	$4.9M-25.0%	$6.5M-26.8%	$8.8M+9.9%	$8.1M-5.9%	$8.6M+181.1%	$3.0M-4.0%	$3.2M
Operating Income	N/A	-$37.1M-34.5%	-$27.6M+12.0%	-$31.4M-13.3%	-$27.7M-34.9%	-$20.5M-40.5%	-$14.6M+15.4%	-$17.3M-51.0%	-$11.4M-49.5%	-$7.6M+4.0%	-$8.0M+37.5%	-$12.8M-4.8%	-$12.2M-12.9%	-$10.8M-112.8%	-$5.1M-47.8%	-$3.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$16K+4280.3%	$360-97.0%	$12K-33.1%	$18K
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	$0	$0	$0	$0	$0
Net Income	N/A	-$34.8M-36.3%	-$25.5M+15.3%	-$30.1M-11.6%	-$27.0M-30.8%	-$20.6M-15.6%	-$17.8M-3.4%	-$17.2M-51.2%	-$11.4M-40.4%	-$8.1M-27.5%	-$6.4M+59.6%	-$15.8M-7.5%	-$14.7M-35.9%	-$10.8M-112.3%	-$5.1M-47.6%	-$3.4M
EPS (Diluted)	—	-$4.04-32.9%	-$3.04	-$0.24-14.3%	-$0.21	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
R&D Expenses	$4.9M+2.5%	$4.8M	N/A	$5.4M-2.4%	$5.5M+32.4%	$4.2M	N/A	$3.4M
SG&A Expenses	$3.8M-25.4%	$5.1M	N/A	$3.9M+9.7%	$3.5M+8.6%	$3.3M	N/A	$3.0M
Operating Income	-$8.7M+11.9%	-$9.9M	N/A	-$9.3M-2.3%	-$9.0M-21.9%	-$7.4M	N/A	-$6.4M
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$8.5M+11.5%	-$9.6M	N/A	-$8.7M-3.2%	-$8.4M-25.4%	-$6.7M	N/A	-$7.2M
EPS (Diluted)	-$0.95+14.4%	-$1.11	N/A	-$0.07	-$0.98-25.6%	-$0.78	N/A	-$0.06

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

ATOS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATOS annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$47.6M-37.7%	$76.4M-20.6%	$96.3M-22.1%	$123.5M-12.6%	$141.3M+229.8%	$42.8M+195.6%	$14.5M+23.6%	$11.7M+43.6%	$8.2M+97.0%	$4.1M-33.6%	$6.2M-46.9%	$11.8M-2.0%	$12.0M+75.9%	$6.8M+122.2%	$3.1M
Current Assets	$45.6M-38.7%	$74.5M-19.3%	$92.2M-22.0%	$118.2M-16.3%	$141.2M+230.2%	$42.8M+198.7%	$14.3M+24.0%	$11.5M+46.2%	$7.9M+142.7%	$3.3M-24.2%	$4.3M-54.0%	$9.3M+38.1%	$6.8M+239.9%	$2.0M-32.5%	$2.9M
Cash & Equivalents	$41.3M-41.9%	$71.1M-19.6%	$88.5M-20.2%	$110.9M-18.7%	$136.4M+244.8%	$39.6M+214.4%	$12.6M+21.2%	$10.4M+43.8%	$7.2M+138.4%	$3.0M-18.5%	$3.7M-56.3%	$8.5M+34.0%	$6.3M+267.6%	$1.7M-9.7%	$1.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$9K	$0	$0	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$298K+114.2%	$139K-1.8%	$142K+11474.0%	$1K
Total Liabilities	$8.3M+66.2%	$5.0M-5.1%	$5.2M-6.0%	$5.6M+78.1%	$3.1M-80.1%	$15.7M+1074.9%	$1.3M-54.2%	$2.9M+137.9%	$1.2M+17.0%	$1.0M-58.1%	$2.5M+10.4%	$2.3M+61.0%	$1.4M-14.7%	$1.7M+9.2%	$1.5M
Current Liabilities	$8.3M+66.2%	$5.0M-5.1%	$5.2M-6.0%	$5.6M+78.1%	$3.1M-80.1%	$15.7M+1084.7%	$1.3M-54.6%	$2.9M+137.9%	$1.2M+17.0%	$1.0M-58.1%	$2.5M+10.5%	$2.3M+61.5%	$1.4M-15.1%	$1.7M+9.2%	$1.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$49K+745.6%	$6K	N/A	N/A
Total Equity	$39.4M-44.9%	$71.5M-21.5%	$91.0M-22.8%	$118.0M-14.6%	$138.1M+408.5%	$27.2M+106.5%	$13.2M+49.4%	$8.8M+26.9%	$6.9M+124.0%	$3.1M-17.2%	$3.7M-60.6%	$9.5M-10.4%	$10.6M+104.8%	$5.2M+231.8%	$1.6M
Retained Earnings	-$246.6M-16.4%	-$211.8M-13.7%	-$186.3M-19.3%	-$156.2M-20.9%	-$129.2M-15.5%	-$111.9M-19.0%	-$94.1M-22.4%	-$76.8M-17.4%	-$65.4M-14.2%	-$57.3M-12.5%	-$50.9M-44.8%	-$35.2M-71.4%	-$20.5M-110.8%	-$9.7M-109.2%	-$4.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$32.3M-14.9%	$37.9M-20.3%	$47.6M-17.9%	$58.0M-10.1%	$64.5M-8.8%	$70.7M-7.5%	$76.4M-3.8%	$79.5M
Current Assets	$31.0M-15.4%	$36.7M-19.6%	$45.6M-18.1%	$55.7M-10.9%	$62.5M-9.1%	$68.7M-7.7%	$74.5M-3.4%	$77.1M
Cash & Equivalents	$26.1M-17.7%	$31.7M-23.2%	$41.3M-20.3%	$51.8M-10.4%	$57.9M-11.1%	$65.1M-8.4%	$71.1M-4.9%	$74.8M
Total Liabilities	$5.5M-26.9%	$7.5M-9.7%	$8.3M+0.4%	$8.2M+20.6%	$6.8M+25.7%	$5.4M+9.2%	$5.0M-14.3%	$5.8M
Current Liabilities	$5.5M-26.9%	$7.5M-9.7%	$8.3M+0.4%	$8.2M+20.6%	$6.8M+25.7%	$5.4M+9.2%	$5.0M-14.3%	$5.8M
Total Equity	$26.8M-12.0%	$30.5M-22.5%	$39.4M-21.0%	$49.8M-13.7%	$57.7M-11.7%	$65.3M-8.6%	$71.5M-3.0%	$73.7M
Retained Earnings	-$264.6M-3.3%	-$256.2M-3.9%	-$246.6M-4.6%	-$235.6M-3.8%	-$226.9M-3.9%	-$218.5M-3.2%	-$211.8M-3.1%	-$205.4M

Not reported in any period shown, so not listed: Goodwill.

ATOS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ATOS annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$35.8M	-$29.8M-41.5%	-$21.0M-0.4%	-$20.9M-0.9%	-$20.8M-26.0%	-$16.5M-42.4%	-$11.6M-26.7%	-$9.1M-1.9%	-$9.0M-35.9%	-$6.6M-22.7%	-$5.4M+61.5%	-$14.0M-32.2%	-$10.6M-19.5%	-$8.8M-126.4%	-$3.9M-11.7%	-$3.5M
Capital Expenditures	$14K	$23K+21.1%	$19K+35.7%	$14K-48.1%	$27K+200.0%	$9K0.0%	$9K+18.0%	$8K-93.1%	$111K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$35.8M	-$29.8M-41.5%	-$21.0M-0.4%	-$21.0M-0.8%	-$20.8M-26.1%	-$16.5M-42.3%	-$11.6M-26.7%	-$9.1M-0.7%	-$9.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$14K	-$23K-21.1%	-$19K-35.7%	-$14K+99.7%	-$4.7M-52422.2%	-$9K0.0%	-$9K-18.0%	-$8K+93.1%	-$111K	N/A	-$9K+96.8%	-$288K+16.0%	-$343K	N/A	-$135K+1.7%	-$137K
Financing Cash Flow	$4.0M	$0-100.0%	$3.7M+349.0%	-$1.5M	$0-100.0%	$113.3M+193.9%	$38.6M+240.1%	$11.3M-7.8%	$12.3M+14.0%	$10.8M+129.6%	$4.7M	N/A	N/A	N/A	$3.8M-30.4%	$5.5M
Share Buybacks	N/A	N/A	$0-100.0%	$1.5M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$9.6M-0.7%	-$9.6M+9.1%	-$10.5M-75.5%	-$6.0M+17.3%	-$7.3M-21.8%	-$6.0M+15.5%	-$7.1M-48.4%	-$4.8M
Capital Expenditures	$0	$0-100.0%	$7K0.0%	$7K	$0-100.0%	$9K	$0-100.0%	$10K
Free Cash Flow	-$9.6M-0.7%	-$9.6M+9.2%	-$10.5M-75.4%	-$6.0M+17.2%	-$7.3M-21.6%	-$6.0M+15.4%	-$7.1M-48.1%	-$4.8M
Investing Cash Flow	$0	$0+100.0%	-$7K0.0%	-$7K	$0+100.0%	-$9K	$0+100.0%	-$10K
Financing Cash Flow	$4.0M	$0	$0	$0	$0	$0-100.0%	$3.4M	$0

Not reported in any period shown, so not listed: Dividends Paid.

ATOS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

ATOS annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-7431.9%	100.0%+78.3pp	21.7%-64.7pp	86.4%	-6379.3%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-725746.2%	-30323.0%	-1704.9%	-1052.0%	-228612.7%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-896491.6%	-36518.8%	-1704.9%	-1054.3%	-229484.5%
Return on Equity	-88.3%-52.7pp	-35.7%-2.6pp	-33.1%-10.2pp	-22.9%-7.9pp	-14.9%+50.7pp	-65.6%+65.4pp	-131.0%-1.5pp	-129.5%-12.5pp	-117.1%+88.6pp	-205.6%+215.6pp	-421.2%-266.9pp	-154.3%-52.6pp	-101.7%-3.6pp	-98.2%+122.5pp	-220.7%
Return on Assets	-73.0%-39.7pp	-33.4%-2.1pp	-31.3%-9.4pp	-21.8%-7.2pp	-14.6%+27.0pp	-41.6%+77.4pp	-119.0%-21.7pp	-97.3%+2.2pp	-99.5%+54.2pp	-153.7%+98.8pp	-252.4%-127.8pp	-124.6%-34.8pp	-89.8%-15.4pp	-74.4%+37.6pp	-112.1%
Current Ratio	5.53-9.5x	14.99-2.6x	17.61-3.6x	21.23-24.0x	45.18+42.5x	2.73-8.1x	10.83+6.9x	3.96-2.5x	6.45+3.3x	3.11+1.4x	1.72-2.4x	4.13-0.7x	4.82+3.6x	1.21-0.7x	1.95
Debt-to-Equity	0.21+0.1x	0.070.0x	0.060.0x	0.050.0x	0.02-0.6x	0.58+0.5x	0.10-0.2x	0.33+0.2x	0.18-0.2x	0.34-0.3x	0.67+0.7x	0.010.0x	0.00-0.3x	0.32-0.7x	0.97

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-31.6%-0.2pp	-31.4%	N/A	-17.5%-2.9pp	-14.6%-4.3pp	-10.3%	N/A	-9.8%
Return on Assets	-26.3%-1.0pp	-25.3%	N/A	-15.0%-1.9pp	-13.1%-3.6pp	-9.5%	N/A	-9.1%
Current Ratio	5.69+0.8x	4.92-0.6x	5.53-1.2x	6.77-2.4x	9.17-3.5x	12.67-2.3x	14.99+1.7x	13.30
Debt-to-Equity	0.200.0x	0.240.0x	0.210.0x	0.170.0x	0.120.0x	0.080.0x	0.070.0x	0.08

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin.

Similar Companies

Pyxis Oncology, Inc. PYXS

$281.1M

Adagene Inc. ADAG

$272.2M

Spero Therapeuti SPRO

$71.6M

Alto Neuroscienc ANRO

$1.4B

Macrogenics Inc MGNX

$265.6M

Where Atossa Therapeutics Inc Ranks

Frequently Asked Questions

Is Atossa Therapeutics Inc profitable?

No, Atossa Therapeutics Inc (ATOS) reported a net income of -$34.8M in fiscal year 2025.

What is Atossa Therapeutics Inc's EBITDA?

Atossa Therapeutics Inc (ATOS) had EBITDA of -$37.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Atossa Therapeutics Inc's return on equity (ROE)?

Atossa Therapeutics Inc (ATOS) has a return on equity of -88.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Atossa Therapeutics Inc's free cash flow?

Atossa Therapeutics Inc (ATOS) recorded an outflow of $29.8M in free cash flow during fiscal year 2025. This represents a -41.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Atossa Therapeutics Inc's operating cash flow?

Atossa Therapeutics Inc (ATOS) recorded an outflow of $29.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Atossa Therapeutics Inc's total assets?

Atossa Therapeutics Inc (ATOS) had $47.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Atossa Therapeutics Inc's capital expenditures?

Atossa Therapeutics Inc (ATOS) invested $23K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Atossa Therapeutics Inc spend on research and development?

Atossa Therapeutics Inc (ATOS) invested $21.2M in research and development during fiscal year 2025.

How many shares does Atossa Therapeutics Inc have outstanding?

Atossa Therapeutics Inc (ATOS) had 9M shares outstanding as of fiscal year 2025.

What is Atossa Therapeutics Inc's current ratio?

Atossa Therapeutics Inc (ATOS) had a current ratio of 5.53 as of fiscal year 2025, which is generally considered healthy.

What is Atossa Therapeutics Inc's debt-to-equity ratio?

Atossa Therapeutics Inc (ATOS) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Atossa Therapeutics Inc's return on assets (ROA)?

Atossa Therapeutics Inc (ATOS) had a return on assets of -73.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Atossa Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Atossa Therapeutics Inc (ATOS) had $41.3M in cash against an annual operating cash burn of $29.8M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Atossa Therapeutics Inc's Piotroski F-Score?

Atossa Therapeutics Inc (ATOS) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Atossa Therapeutics Inc's earnings high quality?

Atossa Therapeutics Inc (ATOS) reported a net loss of $34.8M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.